What an mRNA melanoma vaccine may mean for cancer treatment
Summary
Science Friday explores a breakthrough personalized mRNA melanoma vaccine developed by Moderna and Merck. Guest Dr. Michael Postow from Memorial Sloan Kettering explains how the therapy uses tumor sequencing to boost immune responses against specific cancer mutations. The discussion covers the vaccine’s combination with Keytruda, its potential for other cancers, and the timeline for FDA approval and patient access.
Topics discussed
Sponsors and show introduction
New mRNA melanoma vaccine headlines
How personalized cancer vaccines are made
Cost and therapeutic vs preventive nature
Potential for other cancers and why melanoma first
Combination with Keytruda and trial design
Recurrence-free survival data details
Side effects and patient tolerance
FDA approval timeline and availability
Impact on patients and closing remarks
Listen ad-free on Castria